ライフサイエンスコーパス: DOTATATE

1 [(177)Lu-DOTA(0),Tyr(3)]octreotate ((177)Lu-DOTATATE).

2 n nontumor tissue was higher than for (68)Ga-DOTATATE.

3 of the current clinical gold standard (68)Ga-DOTATATE.

4 uroendocrine tumors, who were evaluated with DOTATATE.

5 n only one of the scans were found by (64)Cu-DOTATATE.

6 24, 96, and 168 h after infusion of (177)Lu-DOTATATE.

7 crine tumors treated with PRRT using (177)Lu-DOTATATE.

8 dy images for both (68)Ga-DOTATOC and (68)Ga DOTATATE.

9 though lower than those observed with (68)Ga-DOTATATE.

10 and patient selection for PRRT with (177)Lu-DOTATATE.

11 er cumulated decay than (111)In- and (177)Lu-DOTATATE.

12 .7-10.6 times higher tumor dose than (177)Lu-DOTATATE.

13 slightly but significantly higher for (68)Ga-DOTATATE.

14 ant clinical role in combination with (68)Ga-DOTATATE.

15 was compared with the SSTR2 agonist (177)Lu-DOTATATE.

16 icantly more lesions were detected by (64)Cu-DOTATATE.

17 roendocrine tumors to receive either (177)Lu-Dotatate (116 patients) at a dose of 7.4 GBq every 8 wee

18 polycythemia prospectively underwent (68)Ga-DOTATATE (13 patients), (18)F-FDG (13 patients), (18)F-f

19 s)-DTyr-NH2] ((177)Lu-DOTA-JR11) and (177)Lu-DOTATATE, 3-dimensional voxel dosimetry analysis based o

20 e-dose GMX1778, 28 d for single-dose (177)Lu-DOTATATE, 35 d for 3 weekly doses of GMX1778, and 98 d f

21 dy tested the efficacy of gallium-68-labeled DOTATATE ((68)Ga-DOTATATE), a somatostatin receptor subt

22 statin analogs (e.g., (68)Ga-DOTATOC, (68)Ga-DOTATATE, (68)Ga-DOTANOC, and (64)Cu-DOTATATE) now offer

23 treated with semiefficient doses of (177)Lu-DOTATATE (7.5 MBq, intravenously) or the nicotineamide p

24 atients had PHD after treatment with (177)Lu-DOTATATE: 8 patients (2.9%) developed a hematopoietic ne

25 iagnostic sensitivity and accuracy of (64)Cu-DOTATATE (97% for both) were significantly better than t

26 icacy of gallium-68-labeled DOTATATE ((68)Ga-DOTATATE), a somatostatin receptor subtype-2 (SST2)-bind

27 Conclusion:(68)Ga-DOTATATE activity on PET in recently symptomatic carotid

28 ts, and explored the mechanism of any plaque DOTATATE activity with immunohistochemistry in resected

29 on of 202 MBq (range, 183-232 MBq) of (64)Cu-DOTATATE after a diagnostic contrast-enhanced CT scan.

30 ivo biodistribution studies comparing (68)Ga-DOTATATE agonist with (68)Ga-DOTA-JR11 and (68)Ga-NODAGA

31 was shown to be less effective than (177)Lu-DOTATATE alone.

32 s results from first-in-humans use of (64)Cu-DOTATATE, an avidly binding somatostatin receptor ligand

33 head-to-head basis the performance of (64)Cu-DOTATATE and (111)In-diethylenetriaminepentaacetic acid

34 The (68)Ga-DOTATATE and (18)F-FDG PET/CT findings were discordant i

35 This study aimed to compare (68)Ga-DOTATATE and (18)F-FDG PET/CT in GEPNETs and to investig

36 Combined (68)Ga-DOTATATE and (18)F-FDG PET/CT is helpful in the individu

37 The relation between complementary (68)Ga-DOTATATE and (18)F-FDG PET/CT results of 27 GEPNET patie

38 The sensitivity of (68)Ga-DOTATATE and (18)F-FDG PET/CT was 95% and 37%, respectiv

39 ndocrine tumors (NETs) underwent both (68)Ga-DOTATATE and (18)F-FDG PET/CT.

40 imed to assess the clinical impact of (68)Ga-DOTATATE and (18)F-FDG with respect to the management pl

41 additional true lesions were found by (64)Cu-DOTATATE and (68)Ga-DOTATOC in 13 and 3 patients, respec

42 nt-based sensitivity was the same for (64)Cu-DOTATATE and (68)Ga-DOTATOC in this cohort, significantl

43 r a typical 100-MBq administration of (68)Ga-DOTATATE and (68)Ga-DOTATOC is 2.1 mSv for both tracers.

44 e NET patients were scanned with both (64)Cu-DOTATATE and (68)Ga-DOTATOC PET/CT and compared on a hea

45 e NET patients were scanned with both (64)Cu-DOTATATE and (68)Ga-DOTATOC PET/CT and compared on a hea

46 ns were concordantly detected on both (64)Cu-DOTATATE and (68)Ga-DOTATOC PET/CT scans, whereas an add

47 ns were concordantly detected on both (64)Cu-DOTATATE and (68)Ga-DOTATOC PET/CT scans, whereas an add

48 , such as 0.021 +/- 0.003 mSv/MBq for (68)Ga-DOTATATE and (68)Ga-DOTATOC, mainly because of higher up

49 (177)Lu-DOTATATE and (68)Ga-DOTATOC/(68)Ga-DOTATATE are used, re

50 r-to-kidney dose ratio compared with (177)Lu-DOTATATE and (90)Y-OPS201.

51 found between 1 and 2a (P > 0.05) for (68)Ga-DOTATATE and 2a and 2b (P = 0.484) for (18)F-FDG.

52 After (177)Lu-DOTATATE and 3 weekly doses of GMX1778, none of the tumo

53 lesion was 95%, 95%, 90%, and 93% for (68)Ga-DOTATATE and 40%, 28%, 28%, and 75% for (18)F-FDG, respe

54 and 98 d for combined treatment with (177)Lu-DOTATATE and GMX1778 x 1.

55 l patients underwent both PET/CT with (64)Cu-DOTATATE and SPECT/CT with (111)In-DTPA-OC within 60 d.

56 ine tumors underwent both PET/CT with (64)Cu-DOTATATE and SPECT/CT with our current routine imaging a

57 str agonists, such as (68)Ga-DOTATOC, (68)Ga-DOTATATE, and [(68)Ga-DOTA,1-Nal(3)]octreotide ((68)Ga-D

58 (18)F-FDA are superior to (18)F-FDG, (68)Ga-DOTATATE, and CT/MRI and should be the radiopharmaceutic

59 (68)Ga-DOTATATE approval by the U.S. Food and Drug Administrati

60 (68)Ga-DOTATOC and (68)Ga-DOTATATE are 2 radiolabeled somatostatin analogs for in

61 (68)Ga-DOTATOC and (68)Ga-DOTATATE are radiolabeled somatostatin analogs used for

62 (68)Ga-DOTATOC and (68)Ga-DOTATATE are suited equally well for staging and patient

63 (177)Lu-DOTATATE and (68)Ga-DOTATOC/(68)Ga-DOTATATE are used, respectively, for PRRT and PET examin

64 sitate to recommend implementation of (64)Cu-DOTATATE as a replacement for (111)In-DTPA-OC.

65 -DTPA-OC) as a basis for implementing (64)Cu-DOTATATE as a routine.

66 mors treated with repeated cycles of (177)Lu-DOTATATE at 8-wk intervals.

67 STR volume between (68)Ga-DOTATOC and (68)Ga-DOTATATE at any time point.

68 ATATE PET/CT image analysis and total (68)Ga-DOTATATE-Avid tumor volume ((68)Ga-DOTATATE TV) was dete

69 We confirmed (68)Ga-DOTATATE binding in macrophages and excised carotid plaq

70 Uptake of (64)Cu-DOTATATE, but not of (68)Ga-DOTATOC, was correlated with

71 Reporting of measured dosimetry of (68)Ga-DOTATATE could be useful for investigations for diagnosi

72 Cobalt-labeled DOTATATE, DOTATOC, and DOTANOC were prepared with (57)Co

73 T/CT 4 d after the administration of (177)Lu-DOTATATE/DOTATOC provides a 3-dimensional dose map and c

74 risks and benefit of treatment with (177)Lu-DOTATATE/DOTATOC.

75 (68)Ga-DOTATATE estimated sensitivity, 90.9% (95% confidence in

76 scanning window of at least 3 h make (64)Cu-DOTATATE favorable and easy to use in the clinical setti

77 Referring physicians categorized the DOTATATE findings on the basis of the written PET report

78 diotracers; and in 50 (48.1%), on the (68)Ga-DOTATATE findings.

79 th the current clinical gold standard (68)Ga-DOTATATE for high-quality imaging of somatostatin recept

80 ficacy and safety supports the use of (68)Ga-DOTATATE for imaging of NETs where it is available.

81 DOTA-derived somatostatin analogs DOTATOC or DOTATATE for PET.

82 We performed a systematic review of (68)Ga-DOTATATE for safety and efficacy compared with octreotid

83 ns study supports the clinical use of (64)Cu-DOTATATE for SRI with excellent imaging quality, reduced

84 ecanetetraacetic acid tyrosine-3-octreotate (DOTATATE) for the treatment of neuroendocrine tumours an

85 interval [CI], 50.0 to 76.8) in the (177)Lu-Dotatate group and 10.8% (95% CI, 3.5 to 23.0) in the co

86 survival, 14 deaths occurred in the (177)Lu-Dotatate group and 26 in the control group (P=0.004).

87 9%, respectively, of patients in the (177)Lu-Dotatate group as compared with no patients in the contr

88 The response rate was 18% in the (177)Lu-Dotatate group versus 3% in the control group (P<0.001).

89 intramuscularly at a dose of 30 mg) ((177)Lu-Dotatate group) or octreotide LAR alone (113 patients) a

90 in less than 10% of patients in the (177)Lu-Dotatate group.

91 Conclusion:(64)Cu-DOTATATE has advantages over (68)Ga-DOTATOC in the detec

92 labeled synthetic somatostatin analog (68)Ga-DOTATATE has not been reported in the peer-reviewed lite

93 PET using the SSTR2 analog (68)Ga-DOTATATE has recently been introduced for imaging of men

94 and [(68)Ga-DOTA,Tyr(3)]-octreotate ((68)Ga-DOTATATE) have shown promising results in patients with

95 In 84 patients (75%), (64)Cu-DOTATATE identified more lesions than (111)In-DTPA-OC an

96 (68)Ga-DOTATATE imaging changed management in 36 patients (70.6

97 o direct comparison of octreotide and (68)Ga-DOTATATE imaging for diagnosis and staging in an unbiase

98 (68)Ga-DOTATATE imaging is a promising approach for detecting G

99 compared with (111)In-pentetreotide, (68)Ga-DOTATATE imaging should be used instead of (111)In-pente

100 ously shown the clinical potential of (64)Cu-DOTATATE in a small first-in-human feasibility study.

101 of the PET tracers (68)Ga-DOTATOC and (64)Cu-DOTATATE in large arteries, in the assessment of atheros

102 cases (36%) lesions were detected by (64)Cu-DOTATATE in organs not identified as disease-involved by

103 ns than the sst2-specific radiotracer (68)Ga-DOTATATE in our patients with GEP-NETs.

104 fficacy and safety of lutetium-177 ((177)Lu)-Dotatate in patients with advanced, progressive, somatos

105 ic dysfunction (PHD) after PRRT with (177)Lu-DOTATATE in patients with gastroenteropancreatic neuroen

106 n, there was a measureable amount of (177)Lu-DOTATATE in patients, which is mainly governed by retent

107 tors, suggesting a potential role for (64)Cu-DOTATATE in the assessment of atherosclerosis.

108 the performance of (68)Ga-DOTATOC and (68)Ga-DOTATATE in the context of subsequent PRRT with (177)Lu-

109 uptake values in PET/CT imaging than (68)Ga-DOTATATE in vivo.

110 edical complications before and after (68)Ga-DOTATATE injection.

111 Importantly, and in contrast to (177)Lu-DOTATATE, injection of 10, 200, and 2,000 pmol of (177)L

112 (64)Cu-DOTATATE is a new PET tracer that has been shown to be f

113 (68)Ga-DOTATATE is an investigational PET/CT imaging agent that

114 receptor radionuclide therapy using (177)Lu-DOTATATE is based on patient imaging during the first we

115 th these results, we demonstrate that (64)Cu-DOTATATE is far superior to (111)In-DTPA-OC in diagnosti

116 The measured human dosimetry of (68)Ga-DOTATATE is similar to that of other (68)Ga-labeled soma

117 ry shows that the critical organ with (68)Ga-DOTATATE is the spleen, followed by the uroepithelium of

118 eceptor imaging with (68)Ga-DOTATATE PET/CT (DOTATATE) is increasingly used for managing patients wit

119 Referring physicians reported that DOTATATE led to a change in suspicion for metastatic dis

120 nflammatory" M1 macrophages, specific (68)Ga-DOTATATE ligand binding to SST2 receptors occurred in CD

121 (68)Ga-DOTATATE mean of maximum tissue-to-blood ratios (mTBRmax

122 (68)Ga-DOTATATE mTBRmax predicted high-risk coronary computed t

123 (n = 8) after the administration of (177)Lu-DOTATATE (n = 22) or (177)Lu-DOTATOC (n = 7).

124 (68)Ga-DOTATATE, (68)Ga-DOTANOC, and (64)Cu-DOTATATE) now offers improved sensitivity.

125 gamma-camera and serum measurements ((111)In-DOTATATE) of patients with meningioma or neuroendocrine

126 OTATOC showed 26 lesions not found on (64)Cu-DOTATATE, of which 7 were found to be true-positive on f

127 rotic inflammation and confirmed that (68)Ga-DOTATATE offers superior coronary imaging, excellent mac

128 after injection of (68)Ga-DOTATOC and (68)Ga-DOTATATE on consecutive days.

129 after injection of (68)Ga-DOTATOC and (68)Ga-DOTATATE on consecutive days.

130 sicians demonstrates a substantial impact of DOTATATE on the intended management of patients with neu

131 ng physicians' perspectives on the impact of DOTATATE on the management of neuroendocrine tumors.

132 rage 367 MBq of (18)F-FDG, 150 MBq of (68)Ga-DOTATATE, or 333.8 MBq of (18)F-fluoro-ethyl-choline; 2.

133 is for both (18)F-FDG (P = 0.037) and (68)Ga-DOTATATE (P = 0.047).

134 ET was 93.5%, compared with 85.5% for (68)Ga-DOTATATE PET (P = 0.005).

135 We validated (68)Ga-DOTATATE PET as a novel marker of atherosclerotic inflam

136 (68)Ga-DOTATATE PET detected 168 of the 226 lesions (74.3%) tha

137 ere reviewed to determine whether the (68)Ga-DOTATATE PET findings resulted in any alteration in mana

138 pared with conventional scintigraphy, (64)Cu-DOTATATE PET identified additional lesions in 6 of 14 pa

139 (68)Ga-DOTATATE PET identified significantly more lesions than

140 cal (111)In-DTPA-octreotide findings, (68)Ga-DOTATATE PET identifies additional lesions and may alter

141 (68)Ga-DOTATATE PET imaging was compared to [(18)F]FDG PET imag

142 We evaluated the role of (68)Ga-DOTATATE PET in a selected group of patients with negati

143 gs substantiate an important role for (68)Ga-DOTATATE PET in meningioma management.

144 ide scintigraphy to determine whether (68)Ga-DOTATATE PET is able to detect additional disease and, i

145 Preoperative MR imaging and (68)Ga-DOTATATE PET scans were fused and used for a spatially p

146 Coronary (68)Ga-DOTATATE PET scans were readable in all patients.

147 NA was highly correlated with in vivo (68)Ga-DOTATATE PET signals (r = 0.89; 95% confidence interval

148 (68)Ga-DOTATATE PET was positive in 41 of these 47 patients (87

149 After (68)Ga-DOTATATE PET, all cases were reviewed to determine wheth

150 TPA-octreotide scintigraphy underwent (68)Ga-DOTATATE PET.

151 Somatostatin receptor imaging with (68)Ga-DOTATATE PET/CT (DOTATATE) is increasingly used for mana

152 (68)Ga-DOTATATE PET/CT and (111)In-pentetreotide scans were obt

153 (68)Ga-DOTATATE PET/CT and (111)In-pentetreotide scans were sig

154 nalyzed the diagnostic performance of (68)Ga-DOTATATE PET/CT and contrast-enhanced MRI (CE-MRI) for t

155 the performance and interpretation of (68)Ga-DOTATATE PET/CT and describes its role in the diagnostic

156 SRS SPECT/CT should be used only when (68)Ga-DOTATATE PET/CT and WB DWI are not available.

157 Therefore, we tested (68)Ga-DOTATATE PET/CT as a tool for improved diagnosis in a co

158 1-2, 2a-2b, and 1-2b with respect to (68)Ga-DOTATATE PET/CT as well as between 1-2a and 1-2b with re

159 (68)Ga-DOTATATE PET/CT changed treatment in 36% of participants

160 (68)Ga-DOTATATE PET/CT combined with CT or liver MRI changed ca

161 o evaluate the safety and efficacy of (68)Ga-DOTATATE PET/CT compared with (111)In-pentetreotide imag

162 (68)Ga-DOTATATE PET/CT correctly identified 3 patients for pept

163 irst 8 y of patient data from a large (68)Ga-DOTATATE PET/CT database in order to establish the impac

164 oms but negative biochemical testing, (68)Ga-DOTATATE PET/CT detected lesions in 65.2% of patients, 4

165 (68)Ga-DOTATATE PET/CT enables detection of meningioma tissue b

166 Conclusion:(68)Ga-DOTATATE PET/CT enables improved detection of the transo

167 ts were selected from 327 consecutive (68)Ga-DOTATATE PET/CT examinations for evaluation of confirmed

168 In four of 14 patients (28.6%), (68)Ga-DOTATATE PET/CT found a previously unknown primary tumor

169 (68)Ga-DOTATATE PET/CT helped identify NET recurrence in 26 of

170 (68)Ga-DOTATATE PET/CT identified more lesions than other imagi

171 (68)Ga-DOTATATE PET/CT identified NET in 29 of the 36 cases and

172 All patients underwent (68)Ga-DOTATATE PET/CT image analysis and total (68)Ga-DOTATATE

173 The interpretation of (68)Ga-DOTATATE PET/CT images for NET staging is consistent amo

174 (68)Ga-DOTATATE PET/CT imaging detected 95.1% of lesions (95% C

175 Current reports suggest that (68)Ga-DOTATATE PET/CT imaging improves diagnosis and staging o

176 (68)Ga-DOTATATE PET/CT imaging provides important information f

177 (68)Ga-DOTATATE PET/CT in comparison to CE-MRI performed at a h

178 te the detectability of lesions using (68)Ga-DOTATATE PET/CT in comparison to SSRS SPECT/CT and WB DW

179 ther validated to substantiate use of (68)Ga-DOTATATE PET/CT in routine follow-up after curative rese

180 spectively compare (68)Ga-DOTANOC and (68)Ga-DOTATATE PET/CT in the same patients with gastroenteropa

181 We evaluated observer agreement for (68)Ga-DOTATATE PET/CT interpretations in patients with neuroen

182 (68)Ga-DOTATATE PET/CT is accurate in detection of recurrent NE

183 determinate tumors suggestive of NET, (68)Ga-DOTATATE PET/CT is highly accurate, thus supporting its

184 (68)Ga-DOTATATE PET/CT of the neck was performed before surgery

185 gated the definite clinical impact of (68)Ga-DOTATATE PET/CT on managing patients with neuroendocrine

186 udy confirmed a significant impact of (68)Ga-DOTATATE PET/CT on the intended management of patients w

187 impact of the combined (18)F-FDG and (68)Ga-DOTATATE PET/CT on the therapeutic decision was 59%.

188 (68)Ga-DOTATATE PET/CT provides information on the location of

189 (68)Ga-DOTATATE PET/CT recordings were obtained in 104 consecut

190 ospectively studied 130 patients with (68)Ga-DOTATATE PET/CT referred for initial or subsequent manag

191 (68)Ga-DOTATATE PET/CT resulted in intended management changes

192 ned by changes in treatment plan when (68)Ga-DOTATATE PET/CT results were added to all prior imaging,

193 during the interval between baseline (68)Ga-DOTATATE PET/CT scan and follow-up imaging (14.0 +/- 6.1

194 Interobserver reproducibility of (68)Ga-DOTATATE PET/CT scan interpretation was measured between

195 uroendocrine tumors and who underwent (68)Ga-DOTATATE PET/CT scanning before and after receiving long

196 We performed measured dosimetry with (68)Ga-DOTATATE PET/CT scanning in 6 volunteer human subjects a

197 (68)Ga-DOTATATE PET/CT scanning is a widely accepted method for

198 (68)Ga-DOTATATE PET/CT scanning is safe and influences manageme

199 Of the 1,258 (68)Ga-DOTATATE PET/CT scans completed, 75.7% were positive and

200 tween May 2005 and August 2013, 1,258 (68)Ga-DOTATATE PET/CT scans were obtained in 728 patients with

201 ors underwent both (68)Ga-DOTATOC and (64)Cu-DOTATATE PET/CT scans, in random order.

202 irect impact on the interpretation of (68)Ga-DOTATATE PET/CT scans.

203 (68)Ga-DOTATATE PET/CT was equivalent or superior to (111)In-pe

204 (68)Ga-DOTATATE PET/CT was performed from head to feet using a

205 (68)Ga-DOTATATE PET/CT was performed on 50 patients with known

206 (68)Ga-DOTATATE PET/CT was prospectively performed in 20 patien

207 vival, and change in management after (68)Ga-DOTATATE PET/CT were evaluated.

208 The most common indications for (68)Ga-DOTATATE PET/CT were follow-up (24.4%) and initial tumor

209 neuroendocrine tumors, we expect that (68)Ga-DOTATATE PET/CT will become the preferred functional ima

210 tomography with computed tomography ((68)Ga-DOTATATE PET/CT) is a sensitive imaging technique for de

211 spective study of patients undergoing (68)Ga-DOTATATE PET/CT, (111)In-pentetreotide single-photon emi

212 On the basis of findings with (68)Ga-DOTATATE PET/CT, 43 of 131 patients (32.8%) had a change

213 and 9 women) underwent SSRS SPECT/CT, (68)Ga-DOTATATE PET/CT, and WB DWI.

214 ceptor scintigraphy [SSRS]) SPECT/CT, (68)Ga-DOTATATE PET/CT, and whole-body diffusion-weighted MR im

215 (68)Ga-DOTATATE PET/CT, SSRS SPECT/CT, and WB DWI demonstrated,

216 vestigated the prognostic accuracy of (68)Ga-DOTATATE PET/CT-based analysis of tumor volume in patien

217 lesions (P = 0.016) were detected on (68)Ga-DOTATATE PET/CT.

218 heochromocytomas/paragangliomas using (68)Ga-DOTATATE PET/CT.

219 ary lesions were identified solely by (68)Ga-DOTATATE PET/CT.

220 NET can be staged with (68)Ga-DOTATATE PET/CT.

221 /=500 scans or >/=5 y experience with (68)Ga-DOTATATE PET/CT; n = 3).

222 e (<500 scans or <5 y experience with (68)Ga-DOTATATE PET/CT; n = 4) or a high level of experience (>

223 ely determine the clinical utility of (68)Ga-DOTATATE positron emission tomography (PET)/computed tom

224 ean age, 58 years) were examined with (68)Ga-DOTATATE positron emission tomography (PET)/computed tom

225 (68)Gallium-DOTATATE positron emission tomography with computed tomo

226 distribution and excretion may render (68)Ga-DOTATATE preferable.

227 SRI with (64)Cu-DOTATATE produced images of excellent quality and high s

228 (slope, 0.88) for (68)Ga-DOTATOC and (68)Ga-DOTATATE, respectively.

229 (slope, 0.88) for (68)Ga-DOTATOC and (68)Ga-DOTATATE, respectively.

230 (slope, 0.74) for (68)Ga-DOTATOC and (68)Ga-DOTATATE, respectively.

231 )Lu-OPS201 than for (90)Y-OPS201 and (177)Lu-DOTATATE, respectively.

232 le-body images for (68)Ga-DOTATOC and (68)Ga-DOTATATE, respectively.

233 Treatment with (177)Lu-Dotatate resulted in markedly longer progression-free su

234 01 (10 pmol) and 6.4 h (5.4-7.3) for (177)Lu-DOTATATE, resulting in a 2.5-times-higher tumor dose for

235 (64)Cu-DOTATATE showed 42 lesions not found on (68)Ga-DOTATOC,

236 Furthermore, (58m)Co-DOTATATE showed considerable therapeutic effects in vitr

237 The mean time interval between the 2 (68)Ga-DOTATATE studies was 9.6 +/- 7.2 mo, and the mean time g

238 dostatin LAR injection and the second (68)Ga-DOTATATE study was 25.1 +/- 14.8 d.

239 est showed significant differences in (68)Ga-DOTATATE SUVmax between tumors with a Ki-67 of less than

240 (68)Ga DOTATATE SUVmax relates to grade and Ki-67 and can be us

241 For (68)Ga-DOTATATE, SUVmax was higher for G1 tumors and lower for

242 ce as many lesions were detected with (64)Cu-DOTATATE than with (111)In-DTPA-OC.

243 ptor radionuclide therapy with (90)Y-labeled DOTATATE, the kidney absorbed dose limits the maximum am

244 euticals in the same patient, finding (68)Ga-DOTATATE to be more sensitive than octreotide.

245 tastasis did not occur in control or (177)Lu-DOTATATE-treated animals, including those where the prim

246 GMX1778 enhances the efficacy of (177)Lu-DOTATATE treatment and induces a prolonged antitumor res

247 neamide phosphoribosyltransferase on (177)Lu-DOTATATE treatment in a NET model.

248 erse correlation between quartiles of (68)Ga-DOTATATE TV and PFS (P = .001) and disease-specific surv

249 emonstrated the prognostic utility of (68)Ga-DOTATATE TV in a large cohort of patients with NETs, in

250 A (68)Ga-DOTATATE TV of 35.8 mL or more was associated with incre

251 A (68)Ga-DOTATATE TV of 7.0 mL or more was associated with higher

252 al (68)Ga-DOTATATE-Avid tumor volume ((68)Ga-DOTATATE TV) was determined.

253 the context of subsequent PRRT with (177)Lu-DOTATATE under standardized conditions in the same patie

254 There was no correlation between (68)Ga-DOTATATE uptake and histologic grade of neuroendocrine t

255 m of this study was to assess whether (68)Ga-DOTATATE uptake before treatment with long-acting somato

256 (68)Ga-DOTATATE uptake correlates with SSTR2 expression and off

257 rospectively evaluated carotid plaque (68)Ga-DOTATATE uptake in patients with recent carotid events,

258 cting octreotide treatment diminished (68)Ga-DOTATATE uptake in the liver, spleen, and thyroid but di

259 (68)Ga-DOTATATE uptake was measured by drawing regions of inter

260 ver, a systematic correlation between (68)Ga-DOTATATE uptake, SSTR2 expression, and histology (includ

261 ere evaluated with (68)Ga-DOTANOC and (68)Ga-DOTATATE using a randomized crossover design.

262 ore and the overall maximum uptake of (64)Cu-DOTATATE using SUV (r = 0.4; P = 0.004) as well as targe

263 al case study examples ((18)F-FDG and (68)Ga-DOTATATE) using the motion-correction technique, demonst

264 ssment of the therapeutic effects of (58m)Co-DOTATATE via DNA double-strand break and proliferation a

265 he prevalence of PHD after PRRT with (177)Lu-DOTATATE was 4% in our patient population.

266 standardized uptake value (SUVmax) of (68)Ga-DOTATATE was correlated with MR imaging findings, histol

267 on of risk factors and maximum SUV of (64)Cu-DOTATATE was found driven by body mass index, smoking, d

268 vascular uptake of (68)Ga-DOTATOC and (64)Cu-DOTATATE was found, with highest uptake of the latter.

269 most common treatment decision due to (68)Ga-DOTATATE was initiation of peptide receptor radionuclide

270 y organs, marginally higher uptake of (68)Ga-DOTATATE was observed in kidneys, bone marrow, and liver

271 Report of harm possibly related to (68)Ga-DOTATATE was rare (6 of 974), and no study reported majo

272 Uptake of (64)Cu-DOTATATE was significantly higher than (68)Ga-DOTATOC in

273 (58m)Co-DOTATATE was significantly more efficient in cell killin

274 ratio for (177)Lu-DOTA-JR11 than for (177)Lu-DOTATATE was the prerequisite for treatment with (177)Lu

275 eutic effect of RAD001 combined with (177)Lu-DOTATATE was, however, not observed in our experiments.

276 therapeutic effects of (111)In- and (177)Lu-DOTATATE were also performed.

277 (68)Ga-DOTANOC and (68)Ga-DOTATATE were false-negative in only 1 of 18 patients.

278 ecific and whole-body dosimetries for (68)Ga-DOTATATE were similar to but often slightly greater than

279 with [(177)Lu-DOTA,Tyr3]octreotate ((177)Lu-DOTATATE), where the latter targets the somatostatin rec

280 a wider receptor binding profile than (68)Ga-DOTATATE, which is sst2-selective.

281 travenous injection of 193-232 MBq of (64)Cu-DOTATATE, whole-body PET scans were acquired at 1 h (n =

282 Labeling of DOTANOC and DOTATATE with (68)Ga was standardized using a fully auto

283 studies reporting safety/toxicity for (68)Ga-DOTATATE with 10 subjects or more thought to have NETs.

284 Nine studies compared (68)Ga-DOTATATE with conventional imaging.

285 dies comparing diagnostic accuracy of (68)Ga-DOTATATE with octreotide or conventional imaging for pul

286 thermore, the clinical performance of (64)Cu-DOTATATE with respect to lesion detection was compared w

287 d basis the diagnostic performance of (64)Cu-DOTATATE with that of (68)Ga-DOTATOC in NET patients.

288 or an injected activity of 200 MBq of (64)Cu-DOTATATE, with the liver being the organ with the highes